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Background: Pulmonary Hypertension (PH) is considered a significant risk factor in patients with aortic valve disease for and the prognostic implicationions of PH are unclear in high-risk patients undergoing Transcatheter Aortic Valve Implantation (TAVI). Therefore, we sought to assessed the impact of preoperative PH on outcome in patients undergoing TAVI. Methods: Between January 2009 and June 2010, a total of 1285 patients undergoing TAVI were included in this registry (mean age 81.7Ϯ6.1, 41.9% males). Patients were grouped according to systolic pulmonary artery pressure (PASP): group I, 277 patients, (21.6%) with PASP Ͻ30mmHg, group II, 598 patients (46.5%) with PASP 30-50 mmHg and group III, 410 patients (31.9%) PASP Ͼ50mmHg. Patients in group III had a significantly higher Euroscore (26Ϯ16mmHG vs. group I 18Ϯ11mmHg vs. group II 18Ϯ11mmHg; pϽ0.0001) and were more symptomatic with a higher proportion presenting in NYHA class IV (28.5% vs. group I 13.6% vs. group II 8.3%; pϽ0.0001). Results: In all subgroups, the majority of procedures was performed transfemorally with a high procedural success rate. The rate of TAVI-associated complications was comparable independent of PASP (cerebrovascular accident: group I 3.3% vs. group II 3.9 % vs. group III 2.0%, pϭ0.25; permanent pacemaker: group I 33.8% vs. group II 38.1 % vs. group III 35.2%, pϭ0.24). Functional NYHA class and survival at 30 days demonstrated excellent outcome in all subgroups (30-day survival group I: 91.2% vs. group II 93.0% vs. group III 91.9%; pϭ0.59). All subgroups experienced a significant improvement of self-assessed quality-of-life (according to EuroQol5d-visual analogue scale) with the largest gain in group III (0.112Ϯ0.35 vs. group I 0.055Ϯ0.32 vs. group II 0.04Ϯ0.32; pϭ0.15).
Conclusions:
In conclusion, non-surgical patients severe AS have a high prevalence of PH. However, based on the registry data, early mortality after TAVI is not increased in patients with PH. This subgroup benefit from the procedure with functional improvement and improved postoperative quality-of-life. NYHA class. AV area significantly improved by 1.2Ϯ0.5 cm2 and mean gradient by 41.7Ϯ16.7 mmHg; 81.6% of patients had Յ mild AR. At 1 year, 93.5% were free from CD, 94.7% from stroke and 78.0% from MACCE. NYHA, AR, AV area and mean gradient improvements persisted at 1 year. PPM rates were evaluated by experience; for Ͻ30 implants, the PPM rate was 33.1%; for Ͼ30 implants; 19.9%. No valve migrations have been reported. Conclusions: Early to midterm outcomes showed mortality and morbidity outcomes within expectations for percutaneously treated patients with severe symptomatic AS in this very high-risk subgroup. Longer term follow-up will be presented at the time of the meeting. Background: Transcatheter aortic valve implantation (TAVI) has emerged as a valuable option to treat patients with symptomatic severe aortic stenosis not being considered for surgery because of significant comorbidities. Concerns exist about treating patients who previously underwent mitral valve surgery for possible interference between the percutaneous aortic valve and the mitral prosthesis or ring. Methods: At our Center from May 2008 one hundred sixty-one patients (74 male) with severe symptomatic aortic stenosis, mean age 81Ϯ9 years, were eligible for TAVI. Nine patients affected by severe aortic stenosis, previously underwent mitral valve surgery (4 mono-leaflet, 3 bi-leaflet, 1 bioprosthesis, 1 mitral ring); they were judged high risk surgical candidates, after combined cardiac surgeons and cardiologist evaluation, and underwent TAVI (Table I) . Results: Seven patients underwent standard femoral retrograde CoreValve implantation, two patient underwent a direct aortic implantation through a mini-thoracotomy. All patients experience immediate improvement of the hemodynamic status. No deformation of the nitinol tubing of the CoreValve neither distortion or malfunction of the mechanical valve or mitral ring occurred as assessed by echographic and fluoroscopic evaluation. No major post-operative complications occurred. In all patients echocardiography evidenced normal valve function during follow-up.
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